Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 16Oxaliplatin 14Nivolumab 14Leucovorin 13pembrolizumab 9Paclitaxel 9Capecitabine 9Radiotherapy 6Radiation 6durvalumab 5Taxes 5Irinotecan 5Cisplatin 5Trastuzumab 4Specimen Handling 4Drug Therapy 4Carboplatin 4tremelimumab 3dehydroftorafur 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Endoscopy 3Docetaxel 3Biopsy 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2tislelizumab 2futibatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × cixutumumab × 1 year × Clear all
NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled 8 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡